Strategic Partnerships Tiba Biotech has active collaboration with the U.S. Army Medical Research Institute of Infectious Diseases and recently expanded with The Pirbright Institute. This indicates a strong channel for co-development programs and government or research-institution funded opportunities that can be mirrored with additional livestock and human health partners seeking preclinical RNA vaccine and delivery solutions.

Livestock Vaccine Focus Recent multi-year collaboration with Pirbright’s Centre for Veterinary Vaccine Innovation and Manufacturing signals a clear entry point into high-impact livestock diseases. Sales opportunities exist in partnerships with veterinary vaccine manufacturers, animal health distributors, and agricultural biotech firms seeking advanced RNA vaccine delivery platforms.

RNA Delivery Platform Tiba’s dendrimer nanoparticle RNA delivery platform and RNABL[TM] indicate a differentiated mechanism potentially attractive to biotech and pharma customers pursuing next-generation RNA therapeutics. This can unlock collaborations with companies looking to improve stability, delivery efficiency, and manufacturability of RNA medicines.

Public and Private Funding With NIH and Gates Foundation funding alongside government grants and BARDA-related activity, there is validated investor and funding attraction. Opportunities exist to pursue co-funded programs, milestone-based partnerships, and grant-supported development deals with public sector entities and industry partners.

Preclinical Positioning As a preclinical stage company, Tiba presents a potential for early-stage collaborations and sponsored research agreements with larger biopharma players seeking access to novel RNA vaccine and therapeutic platforms without full upfront development risk, enabling fast-track collaboration negotiations.